Emerging roles of ILC2s in antitumor immunity  

作　　者：Zhao Li Hanxiao Sun Zhitao Gua Ju Qiu 

机构地区：[1]CAS Key Laboratory of Tissue Microenvironment and Tumor,Shanghai Institute of Nutrition and Health,University of Chinese Academy of Sciences,Chinese Academy of Sciences,Shanghai,200031,China [2]Department of Blood Transfusion,Shanghai Tong Ren Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,200336,China [3]Department of Thoracic Surgery,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai,China

出　　处：《Cellular & Molecular Immunology》2022年第11期1311-1313,共3页中国免疫学杂志（英文版）

基　　金：This work was supported by grants 2020YFA0509103 and 2019YFA0802502 to JQ from the Ministry of Science and Technology of China,grants 32022027 and 31970860 to JQ from the National Natural Science Foundation of China and grants 22ZR1481800 and 20ZR1466900 to JQ from Shanghai Science and Technology Committee(STCSM).

摘　　要：Group 2 innate lymphoid cells(ILC2s)are a subset of ILCs that lack T and B-cell antigen receptors[1].ILC2s share similarities with CD4+T helper 2 cells(Th2)in transcription factor GATA3 expression and signature cytokines production,such as IL-5 and IL-13[1].

关 键 词：ILC2s GATA3 IMMUNITY 

分 类 号：R392[医药卫生—免疫学]